{
    "clinical_study": {
        "@rank": "60605", 
        "brief_summary": {
            "textblock": "To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV\n      human serum."
        }, 
        "brief_title": "Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Proof of HIV infection.\n\n          -  Diagnosis of asymptomatic HIV infection or early AIDS related complex (ARC) with no\n             zidovudine (AZT) or other anti-HIV therapy. OR a diagnosis of AIDS and = or > 3\n             months of AZT therapy.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  HIV-induced neurological disease.\n\n          -  IgA negative.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Immunomodulating agents.\n\n          -  Steroids.\n\n          -  Interferons.\n\n        Patients with the following are excluded:\n\n          -  Active substance abuse.\n\n          -  Use of immunomodulating drugs such as steroids or interferons.\n\n          -  HIV-induced neurological disease.\n\n          -  IgA negative.\n\n        Required with a diagnosis of AIDS:\n\n          -  = or > 3 months of zidovudine (AZT) therapy.\n\n        Active substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "12", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002036", 
            "org_study_id": "060A", 
            "secondary_id": "0001-008"
        }, 
        "intervention": {
            "intervention_name": "Anti-HIV Immune Serum Globulin (Human)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Immune Sera"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Immunization, Passive"
        ], 
        "lastchanged_date": "February 19, 2009", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "Univ of Minnesota"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002036"
        }, 
        "source": "Abbott", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abbott", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2009"
    }, 
    "geocoordinates": {
        "Univ of Minnesota": "44.98 -93.264"
    }
}